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Abstract: Androgen-deprivation therapy (ADT) is used routinely in combination with definitive 
external beam radiation therapy (EBRT) in patients with high-risk clinically localized or locally 
advanced disease. The combined treatment (ADT–EBRT) also seems to play a significant role 
in improving treatment results in the intermediate-risk group of prostate cancer patients. On the 
other hand, there is a growing body of evidence that treatment with ADT can be associated with 
serious and lifelong adverse events including osteoporosis, cardiovascular disease, diabetes, and 
many others. Almost all ADT adverse events are time dependant and tend to increase in severity 
with prolongation of hormonal manipulation. Therefore, it is crucial to clearly state the optimal 
schedule for ADT in combination with EBRT, that maintaining the positive effect on treatment 
efficacy would keep the adverse events risk at reasonable level. To achieve this goal, treatment 
schedule may have to be highly individualized on the basis of the patient-specific potential 
vulnerability to adverse events. In this study, the concise and evidence-based review of current 
literature concerning the general rationales for combining radiotherapy and hormonal therapy, 
its mechanism, treatment results, and toxicity profile is presented.
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Overview
Over the past 2 decades, prostate cancer (PC) patients have become the largest   cancer 
population among all cancer patients in the United States and European Union 
  countries. PC is the second and the third leading cause of cancer deaths in males 
in the United States and European Union countries, respectively.1 The most common 
form of treatment for advanced PC is androgen-deprivation therapy (ADT), which can 
take the form of either surgical castration (orchiectomy) or medical castration (with 
luteinizing hormone-releasing hormone [LHRH] agonist).2 In addition, more and more 
patients with unfavorable intermediate- and high-risk adenocarcinoma of the prostate 
are treated with combination of ADT and primary external beam radiation therapy 
(EBRT), which seems to be the most appropriate treatment.3–5 As shown in a Cancer 
of the Prostate Strategic Urologic Research Endeavor (CaPSURE) report, the use of 
neoadjuvant hormones with radiotherapy (RT) increased from 9.8% to 74.6% during 
1989–1992 and 1999–2001, and from 15.3% to 89.5% during the same periods in 
high-risk patients.6 A report by Shahinian et al indicated that use of ADT increased 
steadily throughout the 1990s among men of all ages with PC who had all stages and 
grades of tumor.7 These numbers highlight the need for good understanding of such 
treatment approach. On the other side, as the role of ADT in the treatment algorithm 
of PC   continues to evolve, there has been increasing attention toward identifying and Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
244
Milecki et al
  preventing   ADT-associated adverse events in recent literature. 
Common side effects associated with ADT include skeletal 
complications, metabolic and   cardiovascular complications, 
sexual dysfunction, hot flashes, periodontal disease, cognition, 
and mood disorders.8,9 Some of the abovementioned adverse 
events can be associated with serious and lifelong disability, 
morbidity, and possibly mortality. Almost all ADT adverse 
events are time dependant and tend to increase in severity 
with prolongation of hormonal manipulation. Therefore, it 
is crucial to clearly state the optimal schedule for ADT in 
combination with EBRT, that maintaining the positive effect 
on treatment efficacy would keep the adverse events risk at a 
reasonable level. To achieve this goal,   treatment schedule may 
have to be highly individualized on the basis of the patient-
specific potential vulnerability to adverse events. In this 
paper, the concise and evidence-based review of   current 
literature concerning the general rationales for combining 
RT and hormonal therapy (HT), its mechanism, treatment 
results, and toxicity profile is presented.
Rationales for combined  
treatment ADT–EBRT
In an early work, Huggins and Hodges stated that male 
hormones promote the growth of both prostate gland and 
cancer cells.10 However, recently it has been recognized 
that the relationship between serum levels of testosterone 
and PC progression is not that straightforward. Very low 
(  castrate) concentrations of serum testosterone are enough to 
fulfill its activating role on the PC cell through the so-called 
  aberrant androgen-signaling pathways.11,12 Moreover, there 
is an   evidence for a significant increase in local synthesis 
of testosterone within prostate stimulated by castrate levels 
of serum hormone.13 Even so, the incomplete eradication 
of testosterone with surgical or pharmacological castration 
has proved to improve the results of RT, and multiple studies 
looked into the possible mechanism and character of that 
interaction.
The idea that ADT added to RT may improve the results 
of combined treatment is based on an earlier experience in the 
application of neoadjuvant HT with surgery.14   Neoadjuvant 
surgical trials have shown response rates (reduction of 
prostate volume, down-staging, and reduction of positive 
margin) approaching 90% when hormonal treatment prior 
to surgery was administered. However, this modality only 
reduces the number of positive postoperative margins after 
radical prostatectomy (RP), but without any influence on 
overall patient survival.15 The mechanism whereby HT 
and RT interact has been studied in vivo in animal models. 
In the original article by Zietman et al, the Shionogi in vivo 
tumor system has provided the basis for our understanding 
of the mechanism behind interplay between ADT and RT. 
The tumors, designed to mimic PC, were implanted into 
severe combined immune-deficient mice.16 Then radiation 
combined with hormonal manipulation (orchiectomy) was 
performed at varying time sequences relative to each other. 
The results showed that ADT improved the tumor response 
to radiation, which was reflected by reduction in the RT dose 
needed to control 50% of tumors (TCD50). Moreover, it was 
observed that when orchiectomy was performed prior to 
RT, much lower doses of radiation were required to achieve 
the given level of tumor control than if performed after or 
during RT. The authors conclude that increased overall cell 
kill seems to be a mechanism responsible for the combined 
effects of ADT and RT. Therefore, the decrease in the number 
of clonogenic cancer cells due to androgen-ablation therapy 
should enhance the effects of RT in tumors at the same dose 
range.17 In another in vivo study, RT and androgen-ablation 
sequencing were evaluated in the R33270G Dunning rat 
prostate tumor model.18 It was found that the median post-
treatment tumor doubling time was significantly longer in the 
group that received RT after neoadjuvant androgen ablation 
compared to all the other treatment groups, including the 
RT with concurrent or adjuvant androgen-deprived groups. 
The possible mechanism of ADT–EBRT interaction in that 
study was the diminished growth velocity of the surviving 
PC cells after neoadjuvant ADT.
Other more clinical observations shed some light on 
ADT–EBRT interactions. Generally, androgen deprivation 
combined with RT is thought to influence the results of 
treatment due to local and/or systemic actions. However, 
whether the increased efficacy of ADT–EBRT is the result 
of an improved local treatment (radiosensitizing effect) or 
systemic eradication of micrometastases or the combination 
of both remains an unanswered question. Obviously, ADT 
leads to shrinkage of the entire prostate gland volume. It has 
very practical implications for RT. First, the field dimensions 
used in RT can be smaller, thereby allowing administra-
tion of a higher total dose without increased side effects to 
healthy tissue.19 Data from numerous studies indicate that 
neoadjuvant HT results in substantial tumor volume reduc-
tion, ranging from 30% to 40%.20 Another postulated mecha-
nism refers to possible enhanced oxygenation (and related 
increased loco-regional RT effectiveness) of the hypoxic PC 
cells by improving blood flow with decreasing interstitial 
pressure when the total amount of cancer cells in the tumor 
is diminished by ADT.21 It is also plausible that apoptosis Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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induced by HT could affect cancer cells in which apoptosis 
was not activated by RT.22 The apoptotic mechanism could 
also be relevant for the systemic interaction of ADT–EBRT 
by prevention of the subsequent distant micro metastases. 
The other systemic interaction scenario includes an increase 
in tumoricidal immune system response, which has been 
postulated to be a low-androgen-dependent state.23
Efficacy of EBRT–ADT combinations
Low-risk PC patients
There is probably no role for ADT in men with low risk 
for biochemical recurrence PC (T1–T2a, Gleason score 
[GS] 6 or below, prostate-specific antigen [PSA] below 10). 
Nevertheless, large number of patients with localized PC are 
receiving ADT as primary or neoadjuvant treatment, yet the 
clinical evidence do not support the use of such treatment. 
As reported by Lu-Yao et al, the ADT as a primary treatment 
for low-risk PC does not improve survival.24 Generally, for 
low-risk PC patients, no published mature data on combined 
EBRT–ADT treatment exist from prospective random-
ized clinical trials. However, the first results of Radiation 
Therapy Oncology Group (RTOG) 94-08 randomized trial, 
which completed accrual in 2001 and has been designed to 
  ascertain whether men with stage T1b–T2 PC and a serum 
PSA of 20 ng/mL or less benefit from the addition of ADT 
given for 4 months before and concomitantly with EBRT, 
has been presented as late-breaking news on recent ASTRO 
2009, in November 2009.25 This landmark study, with 1,979 
participants, is the largest PC study to date among studies 
evaluating ADT–EBRT and is still ongoing. Originally, the 
study was designed to evaluate the treatment of men with 
low-risk PC only, but the definition of low risk evolved as 
the study got underway. About one-third of the patients 
were at low risk (n = 685), which was defined as a GS of 6 
or less with a PSA level of 10 ng/mL or less and a tumor 
stage of T2a or less. About one half of the patients were at 
intermediate risk (n = 1068), which was defined as a GS of 
7, a GS of 6 or less and a PSA of 10–20 ng/mL, or a GS of 
6 or less and stage T2b disease. The remaining patients were 
at high risk (n = 226), with GS of 8–10. Study participants 
were randomized to short-term ADT (2 months before 
and 2 months during radiation) plus radiation therapy, or 
radiation therapy alone. At 8 years, the overall and disease-
specific survival rates in low-risk patients treated with hor-
mones and radiation were comparable to those treated with 
radiation alone. Specifically, the overall survival (OS) rate at 
8 years for patients treated with hormones and radiation was 
76%, compared with 73% for those treated with radiation 
alone (hazard ratio [HR], 1.07; 95% confidence interval 
[CI]: 0.83–1.39). The disease-specific survival rate at 8 years 
for patients treated with hormones and radiation was 98%, 
compared with 99% for those treated with radiation alone 
(HR, 1.07; 95% CI: 0.83–1.39).
Practically, no data or conclusions for low-risk PC 
patients can be pooled out of previous EBRT–ADT trials 
because most of them consisted of patients with T2C or 
higher stage tumors. In a study conducted by Bolla et al 
T1-T2 patients were also included, though only if they were 
also of GS 7–10, which also refers to a higher risk group than 
that deemed low risk according to National Comprehensive 
Cancer Network classification.26
Besides the RTOG trial, the only available evidence for 
the use of combined treatment can be sought in retrospective 
studies. D’Amico and associates reported results of a large 
retrospective study (N = 1586) of men treated with 3D-CRT 
plus or minus ADT for low-risk, intermediate-risk, and high-
risk PC.27 In this study, the median radiation dose was 70.2 
Gy, and ADT was used in 276 men for 2 months before radia-
tion therapy, during treatment, and for 2 months after treat-
ment was completed. With a median follow-up of 51 months, 
the 5-year PSA relapse-free survival for men with low-risk 
PC was 92% with the addition of ADT vs 84% without ADT 
(P = 0.09). The issue of RT–HT in low-risk PC patients was 
also indirectly addressed by a retrospective analysis con-
ducted by Ciezki et al.28 The study included 1,668 patients 
with low- and intermediate-risk PC treated at The Cleveland 
Clinic Foundation with EBRT, RP, or prostate brachytherapy 
with or without androgen deprivation during 1996–2001. The 
5-year biochemical recurrence-free survival (BRFS) rate 
was 90% vs 93% for EBRT alone or with ADT in low-risk   
patients.
intermediate-risk PC patients
None of the completed prospective randomized clinical tri-
als in PC have directly addressed the usage of   EBRT–ADT 
  combination in the group of intermediate-risk patients. 
However, results of three large randomized trials in which 
intermediate-risk patients constituted a significant percent-
age have been published or announced during last few   
years.
Most recently, data from RTOG study 94-08, which 
sought to determine whether 8-week neoadjuvant ADT 
improves RT outcome for patients with clinical stage II PC 
with a low to intermediate relapse risk, were presented on 
ASTRO 51 in Chicago.29 About 54% of the patients accrued 
for that trial were at intermediate risk (n = 1068), which Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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was defined as a GS of 7, a GS of 6 or less and a PSA of 
10–20 ng/mL, or a GS of 6 or less and stage T2b disease. 
In the study, total androgen suppression was achieved with 
flutamide 250 mg twice daily and either goserelin 3.6 mg 
once a month or leuprolide 7.5 mg once a month. The HT 
apparently benefited men with intermediate-risk disease. 
At 8 years, the overall and disease-specific survival rates were 
favorable in intermediate-risk patients treated with hormones 
and radiation, compared with those treated with radiation 
therapy alone. Specifically, the OS rate at 8 years for patients 
treated with hormones and radiation was 72%, compared with 
66% for those treated with radiation alone (HR, 1.23; 95% 
CI: 1.02–1.49). The disease-specific survival rate at 8 years 
for patients treated with hormones and radiation was 98%, 
compared with 92% for those treated with radiation alone 
(HR, 2.44; 95% CI: 1.47–4.04).
The DFCI 95096 trial by D’Amico et al consisted of a 
limited course of androgen deprivation combined with radia-
tion (N = 206) for clinically localized PC (GS . 7 or a serum 
PSA . 10 ng/mL or evidence of extraprostatic   disease). 
Patients were randomized to receive radiation therapy to a 
dose of 70 Gy alone or 70 Gy radiation plus 6 months of 
ADT. Approximately 60% of patients were at intermediate 
risk. At a median follow-up of 4.52 years, men treated with 
the combination of radiation plus androgen deprivation had a 
significantly higher OS than men treated with radiation alone 
(actuarial 5-year survival is 88% vs 78%).30 What is special 
about this trial is that all-cause mortality estimates were strati-
fied by randomized treatment group and further stratified in a 
postrandomization analysis by the comorbidity score. In the 
latest update with a median follow-up of 7.6 (range, 0.5–11.0) 
years, 74 deaths have occurred. A significant increase in the 
risk of all-cause mortality (44 vs 30 deaths; HR, 1.8; 95% 
CI: 1.1–2.9; P = 0.01) was observed in men randomized to 
EBRT compared with EBRT–ADT. However, the increased 
risk in all-cause mortality appeared to apply only to men 
randomized to EBRT with no or minimal comorbidity (31 
vs 11 deaths; HR, 4.2; 95% CI: 2.1–8.5; P , 0.001). Among 
men with moderate or severe comorbidity, those randomized 
to EBRT alone vs   EBRT–ADT did not have an increased risk 
of all-cause mortality (13 vs 19 deaths; HR, 0.54; 95% CI: 
0.27–1.10; P = 0.08). The authors concluded that the addi-
tion of 6 months of ADT to EBRT resulted in increased OS 
in men with localized but unfavorable-risk PC and that this 
result may pertain only to men without moderate or severe   
comorbidity.31
The third trial conducted was performed by The Trans-
Tasman Radiation Oncology Group – TROG 96.01. There 
were 802 men accrued with locally advanced PC of which 
approximately 20% fell into definition of intermediate-risk 
PC.32 The trial had three arms, patients were randomized to 
RT alone, 3 months of neoadjuvant hormones with RT, or 
6 months of neoadjuvant hormones with RT. The protocol 
prescription was 66 Gy to the prostate and seminal vesicles, 
without whole pelvic RT. Five-year PSA disease-free sur-
vival was significantly improved in the both 3-month arm 
(52%; P = 0.002) and 6-month arm (56%; P , 0.0001) as 
compared to the control arm (38%). However, the 6-month 
arm (94%) showed significantly improved prostate-cancer-
specific survival (PCSS; 0.56 [0.32–0.98]; P = 0.04) com-
pared with no androgen deprivation, while for the 3-month 
arm, the PCSS (92%) was not significantly different from 
the control arm (91%). Interestingly, also 5-year distant 
failures were significantly less in the 6-month arm (13%) but 
not for the 3-month arm (22%) as compared to the control   
arm (19%).
Moreover, some data and conclusions about the efficacy 
of EBRT–ADT in this group of patients may be derived 
indirectly from the retrospective subset analyses of previ-
ously described randomized clinical trials because some 
intermediate-risk PC patients were included in RTOG 85-31, 
European Organisation for Research and Treatment of Cancer 
(EORTC) 22863, RTOG 86-10, and RTOG 92-02. In all of 
these trials, investigational arms with EBRT–ADT (or long-
term EBRT–ADT vs short-term EBRT–ADT in the case of 
RTOG 92-02) showed benefit in efficacy end points such as 
local control (LC), progression-free survival (PFS), BRFS, 
and incidence of distant metastases. Moreover, the latest 
update of RTOG 85-31 at the 10-year follow-up showed 
benefit in OS for all patients in the EBRT–ADT arm. The 
subset analysis of RTOG 86-10 at 8 years showed improve-
ment in OS for patients with bulky (T2C–T4) tumors but   
a GS of 2–6.
As for ongoing trials, the definitive results of trial RTOG 
99-10, which already completed accrual for randomized 
Phase III to evaluate the duration of NCHT (8 weeks vs 
28 weeks) with EBRT in intermediate-risk PC patients, are 
still awaited.33 Also, the RTOG 08-15 study is underway to 
evaluate more modern high-dose radiation methods and HT 
in these intermediate-risk patients.34
High-risk PC patients
During the last decade, the results of several prospective 
randomized clinical trials have indicated that combined treat-
ment (androgen ablation plus RT) leads to improved treatment 
results. One of these well-documented clinical trials was Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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carried out by Pilepich et al.35 In this trial (RTOG 8531), the 
influence of androgen depletion combined with RT on the 
results of treatment was evaluated. Patients were randomized 
to receive RT alone or RT plus adjuvant goserelin (LHRH 
agonist), which was introduced in the last week of RT and 
continued until the disease progressed or as long as it was tol-
erated by the patient. RT fields in the first phase of treatment 
  encompassed pelvic lymph nodes, dosed from 44 to 50 Gy, 
followed by an additional dose of 20–25 Gy to the prostate. 
Eligible patients had pelvic lymph node involvement (N1) or 
T3-T4. In the mid 90s, PSA determination became mandatory 
for all patients participating in the trial. At the median follow-
up time of 4.5 years (range; 0.2–9.8 years), 84% of patients on 
the combined therapy arm and 71% of those on the RT-alone 
arm had no evidence of local recurrence (P , 0.0001). The 
update of RTOG trial 85-31 presented in 1999, with a median 
follow-up time of 5.6 years for all patients and 6 years for 
patients who were alive, showed an improvement in cause 
specific survival in the group of patients receiving additional 
HT treatment (P = 0.019).36 The latest update was presented 
in 2005: after 10 years, there was a 10% advantage in OS for 
the HT arm (P = 0.002).37 Patients with GS of 7–10 showed 
the greatest improvement in survival rate. In the next study 
(RTOG 8610) carried out by Pilepich et al, patients received 
neoadjuvant (2 months prior to RT) then androgen ablation 
(goserelin + flutamide) during RT in the study group, and RT 
alone in the control group.38 The RT technique was similar 
to that applied in trials RTOG 8307 and 8531. The results 
of this trial indicated that patients in the combined therapy 
group had better LC, with 5- and 8-year failure rates of 25% 
and 37%, respectively, compared with 36% and 49% in the 
RT-alone group (P , 0.002). The most recent analysis of 
RTOG 86-10 indicated that in patients with GS 7–10, the 
regimen has not resulted in a significant improvement in 
either loco-regional control or survival. However, in patients 
with GS 2–6 tumors, short-course HT administered before 
and during RT resulted in a highly significant improvement 
in OS (70% vs 52%, P = 0.015).39 An interesting analysis 
combining the RTOG 85-31 and RTOG 86-10 trials was 
performed by Horwitz et al.40 According to this study, the 
statistically significant benefit in bNED control (P = 0.0002), 
DMF (P = 0.05), and CSF (P = 0.02) in patients receiving 
long-term HT was limited to centrally reviewed GS 7 and   
8–10 tumors.
The results of the next well-documented randomized 
trial conducted by the EORTC come from Europe. In this 
study, which was reported by Bolla et al, long-lasting 
adjuvant HT during follow-up was compared to follow-up 
without additional HT.41 In the first phase of this trial, gos-
erelin acetate (LHRH analogue) and cyproterone acetate 
(150 mg/d/1 mo) were administered prior to RT concurrently 
during RT in both arms of the study. Thereafter, only in the 
investigational arm, androgen depletion therapy (LHRH 
analogue) was continued for 3 years. Patients in both groups 
received a 50 Gy dose of radiation to the pelvic lymph 
nodes and then an additional 20 Gy dose to the prostate. The 
results of this study were   particularly noteworthy because it 
  compared short   neoadjuvant androgen ablation treatment 
with   long-term   adjuvant therapy. This trial indicated that LC 
in the investigational arm (combined treatment) was 97% 
compared to 77% in the control arm (no further treatment 
after RT) at the 45-month follow-up. The 5-year OS in the 
combined treatment arm was 79% vs 62% in the RT-alone 
group, respectively.
Another important study, reported by Laverdiere et al com-
pared the following three treatment methods: RT alone, 
neoadjuvant-combined androgen blockade (3 months) + RT,   
and neoadjuvant-combined androgen blockade (3 months) + 
RT + adjuvant-combined androgen blockade (10.5 months).42 
The results of this study showed the advantage of neoadjuvant 
and adjuvant HT over RT alone. The study found that patients 
treated with a 64 Gy dose in a combined fashion noted 28% 
positive biopsies compared to 65% treated with RT alone. 
However, the androgen deprivation given 3 months before 
and 6 months after the RT was associated with only a 5% 
rate of positive biopsies. Data concerning the influence of 
combined therapy on treatment outcome are also based on 
observation of 1,554 patients entered in trial RTOG 9202 
conducted by Hanks et al.43 According to the trial protocol, 
all the patients received goserelin and eulexin 2 months 
before and then during RT. After completion of RT, they 
were randomized without any further therapy or were admin-
istered additional goserelin alone for 24 months. The study 
showed that significant improvement in local progression 
rate (6.2% vs 13%), disease-free survival (54% vs 34%), 
freedom from distant metastases (11% vs 17%), and bio-
chemical control (46% vs 21%) was achieved in the group 
of patients who were treated long-term hormonally. It should 
be emphasized that subset analyses (T3, T4, and T2 with GS 
8–10) showed no significant OS difference (77% vs 80%) over   
5 years.
One of the latest randomized clinical trials is the Early 
PC (EPC) program, the largest treatment trial of patients with 
localized or locally advanced PC. The program is helping to 
define which patients benefit, and which do not, from early 
or adjuvant anti-androgen therapy. Third analysis results, Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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at 7.4-years median follow-up, were recently released. 
The program comprises three randomized, double-blind, 
placebo-  controlled trials designed for combined analysis. 
Men (n = 8,113) with localized (T1-2, N0/Nx) or locally 
advanced (T3-4, any N; or any T, N+) PC (all M0) were 
recruited. Patients received bicalutamide 150 mg (n = 4,052) 
or placebo (n = 4,061) once daily plus standard care (RT, RP, 
or watchful waiting [WW]). The primary endpoints were OS 
and objective PFS. Bicalutamide significantly improved OS in 
patients with locally advanced disease who received RT (HR, 
0.65; P = 0.0276); this was driven by a lower risk of death 
due to PC (16.1% vs 24.3%). The ongoing EPC program 
sheds light on the role of anti-androgen therapy and indicates 
significant clinical benefit from the addition of bicalutamide 
150 mg to standard care for patients with locally advanced 
disease; in particular, an OS benefit was seen in men who   
received RT.44
During the last decades, there were a few papers pub-
lished, which showed that long-term adjuvant ADT combined 
with RT for high-risk PC group is related with significant 
improvement in OS. On the other hand, because long-term 
ADT caused several side effects, Bolla et al have conducted a 
randomized clinical trial (EORTC 22961, the so-called Bolla’s 
second trial) in which investigators compared the effects of a 
shorter treatment regimen (6 months of ADT) to long-term 
regimen (36 months of ADT).45 In this non-inferiority trial, 
1,113 patients were included, but 970 patients underwent ran-
domization. Criteria for participation in this trial included T1c 
to T2a–b, pN1 or pN2, M0 or with T2c to T4, cN0 to cN2, and 
M0, baseline level of PSA up to 40 times the upper limit of the 
normal range, and a World Health Organization performance 
status of 0–2. The first 6 months of androgen suppression 
consisted of complete androgen blockade (CAB) with an 
LHRH analogue, initiated on the first day of irradiation, and 
an antiandrogen agent (750 mg of flutamide per day or 50 mg 
of bicalutamide per day), initiated 1 week before the start of 
treatment with the LHRH analogue. The patients assigned to 
long-term suppression continued to be treated with the same 
LHRH analogue but without the antiandrogen for another 2.5 
years. RT was applied in the first phase to the whole pelvis 
(50 Gy) and then to the prostate gland up to 70 Gy in both 
arms. Investigators indicated that after 6.4 years of follow-
up, a 5 years, overall mortality was higher with short-term 
ADT than with long-term ADT, as well PC-specific mortality 
increased by 3.8% and 1.5%, respectively. So, in conclusion 
of this trial, authors stated that a long-term ADT combined 
with RT should be the gold standard for high-risk PC   
patients.
ADT toxicity
Sexual dysfunction
The typical and first described adverse effects of ADT are 
impotence and loss of libido. The relationship between 
androgen ablation and sexual function has been studied in 
several series.46 In one series, Potosky et al compared men 
selecting WW (n = 416) with men selecting ADT (n = 245) 
during the first year following cancer of the prostate (CaP) 
diagnosis.47 Patients completed sexual and quality of life 
surveys at baseline, 6 months postdiagnosis, and 12 months 
postdiagnosis. Among men reporting some sexual interest at 
baseline, 54% of the ADT group vs 13% of the WW group 
reported no interest in sexual activity at approximately 
12 months postdiagnosis (P , 0.001). Among men who 
were potent at baseline, 80% of the ADT group compared 
to 60% of the WW reported impotence at 1-year follow-up 
(P , 0.001). Fowler et al compared health-related quality 
of life (HRQOL) outcomes in androgen-deprived (n = 298) 
and nonandrogen-deprived men (n = 1,095) following RP in 
a survey-based study using Medicare Provider and Analysis 
and Review files. Overall, 166 men in the ADT group and 
886 men in the non-ADT group responded to the survey 
questions regarding erectile dysfunction. Patient receiving 
ADT reported higher rates of postprostatectomy impotence 
(72% vs 55%), but similar rates of impotence over the month 
prior to the survey (23% vs 22%). Regarding the quality of 
erections, 3% (vs 11%) of androgen-deprived men reported 
erections insufficient for intercourse, and only 2% (vs 12%; 
P , 0.0001) reported erections firm enough for intercourse. 
With regard to libido, 69% (of the 170 responders) in the 
ADT group reported no sexual drive over the 30 days prior 
to the survey compared to 29% (of the 888 responders) in 
the non-ADT group (P , 0.0001).48
Quality of life
Currently, no Level I evidence exists that clearly demonstrates 
association of ADT with a decreased HRQOL, and no con-
sensus recommendations are published to   minimize HRQOL-
related adverse effects. Several series have documented an 
association between ADT and declining HRQOL.49 For exam-
ple. Dacal et al compared HRQOL between men undergoing 
short-term ADT (,6 months), long-term ADT (.6 months), 
and healthy controls. When using the MOS questionnaire, 
they found that men   receiving any duration of ADT demon-
strated significantly worsened HRQOL. In particular, ADT 
recipients demonstrated decreased scores in physical compo-
nent health summary (P , 0.001), physical function domain 
(P , 0.001), and general health category (P , 0.001). Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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Notably, a   time-dependent relationship between decreased 
HRQOL and duration of ADT was not   established.50 These 
findings have been supported by other studies demonstrating 
the negative impact of ADT on   cognition, sexual function, 
social interaction, role   functioning, and an increase in the 
level of emotional   distress.51 In   addition to effects on overall 
HRQOL, recent data investigating the association between 
ADT and   psychiatric illness has documented an almost 
twofold increase in the risk of de novo psychiatric   illness 
following ADT induction.
Vasomotor symptoms “hot flashes”
The so-called “hot flashes” or, more precisely,   vasomotor 
flushings are a common and well-described treatment   toxicity 
in men undergoing androgen ablation and are one of the 
most frequently reported adverse consequences of ADT. 
Spetz et al performed a prospective analysis comparing 
the incidence of hot flashes in men receiving CAB to that 
in men receiving estrogen therapy for treatment of PC.52 
In this study, in 915 patients with metastatic disease, 458 
were treated with polyestradiol phosphate and 457 patients 
received CAB. Of men receiving CAB, 74.3% reported hot 
flashes compared to 30.1% in men receiving estrogen therapy 
(P , 0.001). Further, a significantly greater percentage of 
men treated with CAB were “greatly distressed” by the hot 
flashes (11.3% vs 2.6%, P , 0.01) and reported at least 4 hot 
flashes per day (33.7% vs 2.7%, P , 0.001). ADT-associated 
vasomotor flushing remains a common complaint reported 
by men receiving this therapy and is reported in up to 80% of 
men receiving ADT. Interestingly, megestrol acetate has been 
demonstrated to reduce hot flash symptoms by up to 85%. 
On the other hand, chills, weight gain, and carpal tunnel-like 
pain are the reported side effects of megestrol acetate.53
endocrine dysfunction  
and metabolic syndrome
Male hypogonadism is recognized as an independent risk fac-
tor for the development of endocrine dysfunction.54,55 In par-
ticular, there is increasing evidence supporting an association 
between ADT and increased risk of the   metabolic syndrome 
and its associated adverse endocrine and   end-organ effects.56 
Metabolic syndrome is diagnosed when three of five criteria 
proposed by the Adult Treatment Panel III are met, includ-
ing fasting plasma glucose .100 mg/dL, serum triglyceride 
level .150 mg/dL, serum high-density lipoprotein (HDL) 
, 40 mg/dL, waist circumference .102 cm, and blood pres-
sure .130/85. In one study, a significantly higher overall 
prevalence of abdominal obesity (P = 0.007), hyperglycemia 
(P = 0.007), and hypertriglyceridemia (P = 0.06) in ADT 
group was noted – all factors that contribute to the diagnosis 
of metabolic syndrome. Further, the prevalence of the meta-
bolic syndrome was found to be significantly higher in the 
men receiving ADT (55%) compared to both the   non-ADT 
group (22%) and eugonadal controls (20%, P = 0.03). The 
insulin resistance is a major factor of the metabolic syndrome 
and has also been associated with ADT.57 In the study by 
Smith et al, 25 men with locally advanced or recurrent CaP 
and no evidence of metastasis or diabetes were studied for 
ADT-related effects on insulin resistance. Patients received a 
12-week course of CAB (leuprolide depot and bicalutamide) 
and baseline, and follow-up comparisons were made between 
the following parameters: plasma glucose, plasma insulin, 
hemoglobin A1c, lipid profiles, and percentage of body 
fat. Mean percent body fat mass increased 4.3% ± 1.3% 
(P = 0.002) after 3 months, while percent lean body mass 
decreased 1.4% ± 0.5% (P = 0.006). Further, ADT demon-
strated significant effects on all of the lipid indices assessed, 
with rises in total cholesterol (9.4% ± 2.4%, P , 0.001), HDL 
cholesterol (9.9% ± 2.9%, P = 0.01), low-density lipopro-
tein cholesterol (8.7% ± 4.7%, P = 0.09), and triglycerides 
(23% ± 8.0%, P = 0.04). No changes in fasting blood glucose 
were seen during the study; however, significant rises were 
seen in plasma insulin levels (P = 0.04) and mean serum 
HbA1c levels (P , 0.001). Further, insulin sensitivity signifi-
cantly decreased by nearly 13% (P = 0.02), and one patient 
was diagnosed with diabetes mellitus (DM) at the completion 
of the study.58 In another series of 73,196 men with local and 
regional CaP from the Surveillance, Epidemiology, and End 
Results (SEER) database, a significant increase in the inci-
dence of DM was noticed in men receiving ADT (P , 0.001) 
when compared to those not receiving ADT. Further, the 
duration of ADT was identified as a predictor for increased 
risk of subsequent diabetes, even in patients receiving only 
short courses of ADT.
Osteoporosis and skeletal fractures
Osteoporosis in men has gained significant clinical atten-
tion over the last decade. T-score criteria for the diagnosis 
of osteoporosis and osteopenia are still evolving; however, 
it is estimated that using fractures as a clear endpoint for the 
disease, males have a 13%–25% lifetime risk of developing 
osteoporosis. Hypogonadism is well described as one of 
the major causes of osteoporosis in men along with alcohol 
abuse, glucocorticoid excess, low-dietary calcium, vitamin 
D deficiency, and sedentary lifestyle. The increasing use of 
ADT in current practice patterns for the treatment of local Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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and advanced CaP has made ADT one of the leading causes 
of hypogonadism and thus osteoporosis in men.59,60 In a 
contemporary series of 395 men receiving ADT, Malcolm 
et al identified ADT as an independent risk factor for the 
  development of osteoporosis and nonpathologic fractures. 
In this series, 23% of men receiving ADT developed osteo-
porosis, while 7% were diagnosed with nonpathologic 
fractures. Further, duration of ADT was identified to be an 
independent   predictor for the development of osteoporosis 
(P , 0.001) and was on average 49% longer in patients 
diagnosed with fractures (P , 0.001). Importantly, the 
development of osteoporosis was positively associated 
with the development of nonpathologic fractures in this 
cohort (P , 0.001). Another study brought evidence that 
gonadotropin-releasing   hormone (GnRH) agonists increase 
the risk of fractures in men receiving ADT when compared 
to controls.61   Shahinian et al analyzed men with CaP from 
the SEER database to assess osteoporosis and fracture 
risk in the ADT population.62 For men surviving at least 
5 years from CaP diagnosis, the incidence of fractures was 
19.4% for patients treated with GnRH agonists vs 12.6% 
for men treated with other modalities (P , 0.001). Further, 
Cox proportional-hazards regression analyses identified a 
  statistically significant relationship between the number of 
GnRH injections in the first year following diagnosis and 
the risk for developing fractures, after adjusting for other 
  clinicopathologic variables. Smith et al assessed the risk for 
fracture development in men with nonmetastatic disease 
who were treated with ADT.63 Nearly 4,000 men with a 
history of ADT receipt were matched to men receiving no 
form of castration therapy (n = 7,774). Their comparison 
study demonstrated a significantly higher clinical fracture 
risk in the GnRH agonist group (7.88/100 vs 6.51/100 
person-years at risk, P , 0.001). Further, ADT indepen-
dently predicted future fracture risk in multivariate analy-
ses, and longer treatment duration conferred a greater risk 
for subsequent   fractures. The increased fracture rates in 
patients   receiving HT are multifactorial, including higher 
incidence of   metastatic bony lesions,   fragility from disease 
and disease-related treatment, and decreased bone mineral 
density associated with ADT.64
Cardiovascular disease
Several retrospective studies suggested increased risk for 
cardiovascular disease in patients receiving ADT. In a study 
by Malcolm et al, 395 men receiving ADT were reviewed for 
incidence of cerebrovascular accident or myocardial infarc-
tion. Logistic regression demonstrated a time-dependent 
relationship between risk of myocardial infarction (HR, 2.12; 
P = 0.03) and cerebrovascular accident (odds ratio = 3.22, 
P = 0.001) and increasing duration of ADT administration.65 
Further in another study, Keating et al identified a higher 
  incidence of coronary heart disease (HR = 1.16, P , 0.001), 
myocardial infarction (HR = 1.11, P = 0.03), and sudden 
cardiac death (HR = 1.16, P = 0.004) in men receiving 
ADT when compared to a control group. Additionally, the 
increased risk of coronary heart disease remained signifi-
cantly increased even in men receiving ADT for as few as 
1–4 months (HR = 1.29, P , 0.001). Myocardial infarction 
and sudden cardiac death also occurred at higher frequen-
cies in the ADT group when stratified by duration of therapy, 
though this did not demonstrate statistical significance. 
Tsai et al directly examined the relationship between ADT 
and cardiac-related death in an analysis of the CaPSURE 
database.66 Of 4,892 patients with organ-confined CaP, 1,015 
received either neoadjuvant or adjuvant ADT, with median 
therapy duration of 4.1 months, in conjunction with local sur-
gical or radiation treatment. Competing regression analyses 
that controlled for age, ADT administration, and a history 
of heart disease or diabetes mellitus at baseline were used to 
compare cardiac-related mortality rates between men receiv-
ing ADT or treated without castration. The authors found 
that in men treated with RP (n = 3,262), age (HR = 1.07, 
P = 0.003) and ADT use (HR = 2.6, P = 0.002) were signifi-
cantly associated with an increased risk of cardiac-related 
death. Moreover, 5-year cumulative incidence estimates of 
cardiac death were higher in men receiving ADT when strati-
fied by age (P = 0.02 for , 65 years, P = 0.01 for . 65 years). 
On the other hand, results of a recently completed EORTC 
randomized trial (Protocol 22961) comparing RT plus a total 
of 6 months of ADT to RT plus a total of 3 years of ADT 
in patients with locally advanced PC detected no significant 
difference in the incidence of fatal cardiac events at 5-year 
follow-up (4.0% vs 3.0%, respectively). Moreover, the recent 
systematic review performed by panel of specialist recom-
mended that at present, based on the available evidence, it can 
only be stated that ADT may be related with cardiovascular 
disease risk.67
Remarks and conclusions
In the high-risk group of patients, combined treatment 
(RT–HT) produced therapeutic gain. For intermediate-risk 
patients, we have the first results of clinical trials RTOG 
94-08, suggesting a statistically significant benefit. More pre-
cise conclusion can be made after the results of RTOG 99-10 
trial. For low-risk PC patients, combined EBRT–ADT has no Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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role in contemporary treatment guidelines. On the basis of 
the data reviewed from the literature, it can be concluded as   
follows:
1.  ADT is easy to administer and requires no special tech-
nology. Neoadjuvant, concurrent, and long-term adjuvant 
androgen deprivation is standard treatment in conjunction 
with radiation therapy in the group of patients with high 
risk of failure (T3, PSA . 20 ng/mL, GS . 7). Neoad-
juvant, concurrent ADT, and short-term adjuvant should 
be individually decided in intermediate-risk patients.
2.  The optimal timing for application of androgen depletion 
has not yet been precisely determined. According to the 
current state of knowledge, approximately 2–3 months for 
neoadjuvant therapy is probably the optimal strategy. The 
best mode of neoadjuvant HT is represented by chemical 
castration combined with short antiandrogen treatment 
in the initial phase. Neoadjuvant HT should always be 
followed by ADT concurrent with RT. Adjuvant HT is 
recommended for high-risk patients for at least 2 years, but 
longer treatment could be beneficial, provided the toxicity 
of ADT is not of concern because of patient comorbidities. 
Studies have shown a survival benefit for patients with 
more advanced disease when longer adjuvant androgen 
suppression treatment was applied (3 years).
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